OpZira Launches With Goal of Advancing Ocular Disease Detection and Monitoring
Following Alcon’s acquisition of LumiThera, the maker of the Valeda Light Delivery System for the treatment of dry AMD, LumiThera’s diagnostic product lines were spun off to shareholders, forming the foundation of OpZira Inc.
According to an OpZira news release, the company is dedicated to delivering technologies that enhance the detection and monitoring of ocular disease. OpZira enters the market with a portfolio of diagnostic technologies designed to offer objective, reliable insights into retinal and neuro-visual function:
AdaptDx Pro — A wearable dark adaptometer leveraging AI to provide a consistent patient testing experience. Dark adaptation speed, often the earliest functional sign of retinal disease, can help clinicians detect rod-mediated dysfunction before vision loss becomes apparent. AdaptDx Pro is currently available in the U.S.
NOVA Vision Testing System — A comprehensive electrophysiology platform designed to evaluate the entire visual and neuro-visual pathway. The Visual Evoked Potential (VEP) module is available in the US and select international markets, while the Electroretinography (ERG) module is available outside the U.S.
“Building on the LumiThera team’s success in developing the Valeda treatment for early to intermediate dry AMD patients, the OpZira technologies may provide early detection and ongoing monitoring which are important for optimizing patient outcomes,” said Eleonora Lad, MD, PhD, Duke University Medical Center. “Now that there are approved treatment options for dry AMD, having tools that provide objective data to help determine when and how often to treat patients is critical.”
“OpZira was founded to bridge the gap between groundbreaking research and practical clinical tools,” said Clark Tedford, PhD, President & CEO of OpZira. “Our mission is to give eye care professionals the technology they need to detect ocular diseases earlier and monitor them more effectively.”